CENTER OF EXCELLENCE Biopharmapark Dessau

Preserving the health since 1921

IDT Biologika specializes in the contract development and manufacturing of Viral Vaccines, Gene and Immunotherapeutics as well as sterile liquids and lyophilized Biologics. IDT Biologika helps biopharmaceutical and biotech companies as well as the US government as part of research consortia with the challenging and complex process of translating viral vaccines and biopharmaceuticals from the research lab through clinical development to large-scale commercial manufacturing inculding drug substance production, fill & finish, packaging and analytics. IDT Biologika provides fully integrated services for GMP compliant end-to-end services in BSL2 facilites meeting EMA, FDA and ANVISA standards.

IDT Biologika strives for strong, trusting and enduring customer partnerships. Our almost 100 year tradition in manufacturing vaccines and biopharmaceuticals motivates and obligates us to advance our clients’ products to prevent and treat diseases that impact the health of people worldwide.

The cytostatic drug specialist

ONCOTEC Pharma Produktion GmbH specialises in the production and development of aseptically produced cytostatic drugs in bottles and pre-filled syringes. Additionally, special freeze-drying systems make it possible to preserve the bottled liquids immediately.

Since its foundation in 1997, ONCOTEC has guaranteed its partners optimal technological conditions for the production of highly innovative special products, including with continuous investments and modernisations. What is new is a robot-controlled bottling line for special chemotherapeutics, such as highly effective antibody drug conjugates (ADCs).

ONCOTEC thus offers its international customers a full service for the entire value chain of cytostatic drug production – from development to commercial production, including inspection and analysis.

Products in the field of medical aesthetics and neurotoxins

Merz is a Frankfurt-based, globally operating family enterprise in the field of aesthetics and neurotoxins. Innovation, a long-term perspective and a focus on profitable growth characterise the company, which has been privately owned for more than 110 years. In 2002, the pharmaceutical company set up a production site at the Biopharmapark in Dessau that would serve – as a first for the company – to produce the common active agent botulinum neurotoxin.

Shortly thereafter, Merz invested in the development of new products of its own making with the active agent botulinum neurotoxin for the treatment of neurologically induced movement disorders and for use in medical aesthetics, which have since been produced at the production site.  In autumn 2018, Merz further expanded the location and since then it has also produced dermal fillers at the production site in Dessau. As an innovative company, Merz appreciates the Biopharmapark’s close proximity to the world of science, meaning the universities of Halle, Leipzig and Berlin.

Fighting rabies

Ceva - World leader in the fight against rabies

The Ceva Innovation Center GmbH is one of 14 research bases of Ceva Santé Animale. The Ceva Group is present in 46 countries with own subsidiaries and employs 5900 people worldwide. The company focuses on the research, development, production and marketing of pharmaceutical products and vaccines for pets, poultry, ruminants and pigs. In 2019, Ceva Animal Health acquired the animal health division of IDT Biologika and has continued its 25-year tradition of developing oral rabies vaccines. Together with international organizations, Ceva is successfully working towards a world without rabies. Modern third generation vaccines and a unique bait design are the key to success.